WEE1 inhibition sensitizes osteosarcoma to radiotherapy
<p>Abstract</p> <p>Background</p> <p>The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-04-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/156 |
id |
doaj-3f7554069f434ddfa0bf80499aefff9d |
---|---|
record_format |
Article |
spelling |
doaj-3f7554069f434ddfa0bf80499aefff9d2020-11-24T23:44:03ZengBMCBMC Cancer1471-24072011-04-0111115610.1186/1471-2407-11-156WEE1 inhibition sensitizes osteosarcoma to radiotherapyHelder Marco Nvan Beusechem Victor WGraat Harm CAWürdinger ThomasPosthumaDeBoer Jantinevan Royen Barend JKaspers Gertjan JL<p>Abstract</p> <p>Background</p> <p>The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an intralesional resection of the primary tumor. After irradiation-induced DNA damage, OS cells sustain a prolonged G<sub>2 </sub>cell cycle checkpoint arrest allowing DNA repair and evasion of cell death. Inhibition of WEE1 kinase leads to abrogation of the G<sub>2 </sub>arrest and could sensitize OS cells to irradiation induced cell death.</p> <p>Methods</p> <p>WEE1 expression in OS was investigated by gene-expression data analysis and immunohistochemistry of tumor samples. WEE1 expression in OS cell lines and human osteoblasts was investigated by Western blot. The effect of WEE1 inhibition on the radiosensitivity of OS cells was assessed by cell viability and caspase activation analyses after combination treatment. The presence of DNA damage was visualized using immunofluorescence microscopy. Cell cycle effects were investigated by flow cytometry and WEE1 kinase regulation was analyzed by Western blot.</p> <p>Results</p> <p>WEE1 expression is found in the majority of tested OS tissue samples. Small molecule drug PD0166285 inhibits WEE1 kinase activity. In the presence of WEE1-inhibitor, irradiated cells fail to repair their damaged DNA, and show higher levels of caspase activation. The inhibition of WEE1 effectively abrogates the irradiation-induced G<sub>2 </sub>arrest in OS cells, forcing the cells into premature, catastrophic mitosis, thus enhancing cell death after irradiation treatment.</p> <p>Conclusion</p> <p>We show that PD0166285, a small molecule WEE1 kinase inhibitor, can abrogate the G<sub>2 </sub>checkpoint in OS cells, pushing them into mitotic catastrophe and thus sensitizing OS cells to irradiation-induced cell death. This suggests that WEE1 inhibition may be a promising strategy to enhance the radiotherapy effect in patients with OS.</p> http://www.biomedcentral.com/1471-2407/11/156 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Helder Marco N van Beusechem Victor W Graat Harm CA Würdinger Thomas PosthumaDeBoer Jantine van Royen Barend J Kaspers Gertjan JL |
spellingShingle |
Helder Marco N van Beusechem Victor W Graat Harm CA Würdinger Thomas PosthumaDeBoer Jantine van Royen Barend J Kaspers Gertjan JL WEE1 inhibition sensitizes osteosarcoma to radiotherapy BMC Cancer |
author_facet |
Helder Marco N van Beusechem Victor W Graat Harm CA Würdinger Thomas PosthumaDeBoer Jantine van Royen Barend J Kaspers Gertjan JL |
author_sort |
Helder Marco N |
title |
WEE1 inhibition sensitizes osteosarcoma to radiotherapy |
title_short |
WEE1 inhibition sensitizes osteosarcoma to radiotherapy |
title_full |
WEE1 inhibition sensitizes osteosarcoma to radiotherapy |
title_fullStr |
WEE1 inhibition sensitizes osteosarcoma to radiotherapy |
title_full_unstemmed |
WEE1 inhibition sensitizes osteosarcoma to radiotherapy |
title_sort |
wee1 inhibition sensitizes osteosarcoma to radiotherapy |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2011-04-01 |
description |
<p>Abstract</p> <p>Background</p> <p>The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an intralesional resection of the primary tumor. After irradiation-induced DNA damage, OS cells sustain a prolonged G<sub>2 </sub>cell cycle checkpoint arrest allowing DNA repair and evasion of cell death. Inhibition of WEE1 kinase leads to abrogation of the G<sub>2 </sub>arrest and could sensitize OS cells to irradiation induced cell death.</p> <p>Methods</p> <p>WEE1 expression in OS was investigated by gene-expression data analysis and immunohistochemistry of tumor samples. WEE1 expression in OS cell lines and human osteoblasts was investigated by Western blot. The effect of WEE1 inhibition on the radiosensitivity of OS cells was assessed by cell viability and caspase activation analyses after combination treatment. The presence of DNA damage was visualized using immunofluorescence microscopy. Cell cycle effects were investigated by flow cytometry and WEE1 kinase regulation was analyzed by Western blot.</p> <p>Results</p> <p>WEE1 expression is found in the majority of tested OS tissue samples. Small molecule drug PD0166285 inhibits WEE1 kinase activity. In the presence of WEE1-inhibitor, irradiated cells fail to repair their damaged DNA, and show higher levels of caspase activation. The inhibition of WEE1 effectively abrogates the irradiation-induced G<sub>2 </sub>arrest in OS cells, forcing the cells into premature, catastrophic mitosis, thus enhancing cell death after irradiation treatment.</p> <p>Conclusion</p> <p>We show that PD0166285, a small molecule WEE1 kinase inhibitor, can abrogate the G<sub>2 </sub>checkpoint in OS cells, pushing them into mitotic catastrophe and thus sensitizing OS cells to irradiation-induced cell death. This suggests that WEE1 inhibition may be a promising strategy to enhance the radiotherapy effect in patients with OS.</p> |
url |
http://www.biomedcentral.com/1471-2407/11/156 |
work_keys_str_mv |
AT heldermarcon wee1inhibitionsensitizesosteosarcomatoradiotherapy AT vanbeusechemvictorw wee1inhibitionsensitizesosteosarcomatoradiotherapy AT graatharmca wee1inhibitionsensitizesosteosarcomatoradiotherapy AT wurdingerthomas wee1inhibitionsensitizesosteosarcomatoradiotherapy AT posthumadeboerjantine wee1inhibitionsensitizesosteosarcomatoradiotherapy AT vanroyenbarendj wee1inhibitionsensitizesosteosarcomatoradiotherapy AT kaspersgertjanjl wee1inhibitionsensitizesosteosarcomatoradiotherapy |
_version_ |
1725500262021332992 |